ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 306 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is 1.19 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $863 | +145.2% | 32,127 | +131.8% | 0.01% | +166.7% |
| Q1 2023 | $352 | -74.0% | 13,860 | -58.5% | 0.00% | -85.0% |
| Q4 2022 | $1,353 | -99.9% | 33,365 | -51.8% | 0.02% | -33.3% |
| Q3 2022 | $2,290,000 | +37.8% | 69,291 | +46.8% | 0.03% | +50.0% |
| Q2 2022 | $1,662,000 | +448.5% | 47,193 | +617.4% | 0.02% | +400.0% |
| Q1 2022 | $303,000 | -92.2% | 6,578 | -88.8% | 0.00% | -90.0% |
| Q4 2021 | $3,883,000 | +284.5% | 58,567 | +262.1% | 0.04% | +185.7% |
| Q3 2021 | $1,010,000 | +7.6% | 16,174 | +42.7% | 0.01% | +40.0% |
| Q2 2021 | $939,000 | +107.7% | 11,332 | +66.2% | 0.01% | +42.9% |
| Q1 2021 | $452,000 | -45.5% | 6,817 | -36.9% | 0.01% | -12.5% |
| Q4 2020 | $829,000 | +103.2% | 10,807 | -23.9% | 0.01% | -63.6% |
| Q1 2020 | $408,000 | -70.4% | 14,197 | -34.6% | 0.02% | -15.4% |
| Q4 2019 | $1,377,000 | – | 21,716 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
| Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
| L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
| First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
| ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
| Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
| Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
| Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
| Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |